Pfizer (PFE) is down about 3% as the market continues to discount a softer 2026 earnings profile and fading COVID-era cash flows. Investors have been sensitive to any developments that reinforce the view that Pfizer’s near-term growth is constrained by lower expected COVID vaccine and antiviral demand, making guidance credibility and pipeline execution the key swing factors for the stock.

The central overhang is Pfizer’s 2026 financial framework, which has pointed to adjusted EPS below prior market expectations alongside relatively flat revenue expectations, reflecting lower COVID-related contribution and other transition costs. That setup has kept the stock vulnerable to renewed selling on down days for the broader pharma complex and whenever COVID-demand assumptions are revised downward.

Adding to the caution, Pfizer and BioNTech recently halted recruitment for a large U.S. clinical trial of an updated COVID-19 vaccine for adults ages 50–64 due to difficulty enrolling participants, and also planned to stop certain symptom monitoring after early April. While not an efficacy failure, the headline reinforces the reality of a smaller, harder-to-study commercial COVID market and can amplify investor concerns about how quickly Pfizer’s COVID franchise can stabilize at a lower run-rate.

Near-term, investors will watch for any revisions to 2026 COVID-sales assumptions, additional pipeline readouts that can help offset looming revenue headwinds, and changes in Street price targets or ratings that could shift positioning. The next scheduled earnings date visible on major market calendars is early May 2026, which could become the next catalyst for guidance reaffirmation or reset.